Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
High-quality, low-cost bio-CMOs rally forth
October 8, 2009
By: Soman Harachand
Contributing Writer, Contract Pharma
It was probably the French drugmaker Sanofi’s buyout of Shantha Biotechnics in June that suddenly turned the global spotlight on India’s biotech scene. Sanofi’s vaccine unit Sanofi-Pasteur paid a huge premium to Merieux Alliance – which owned majority ofshares in Shantha Bio through its subsidiary ShanH – to acquire controlling stake in the Hyderabad based bio firm. At around $783 million, or roughly eight times more than Shantha’s expected annual $90 million sales in figures, the deal has set a new valuation benchmark for the Indian biotech companies. Justifying the high valuation, Sanofi’s chief executive Christopher Viehbacher said the deal underscored the growing importance of the emerging second wave of strong portfolio based companies from India. Extremely high quality low cost manufacturing capacities made Shantha a good fit for Sanofi as a hub to pursue Sanofi’s global biotech goals, Mr. Viehbacher added. Shantha, which claims to have launched the first desi version of recombinant hepatitis B vaccine in India, has already bagged $340 million worth of three-year contracts from the United Nations to supply a pentavalent vaccine in September. If Shantha-Sanofi deal is any indication, then strong manufacturing capabilities, together with the potential to generate intellectual property, has started attracting strategic investors to India’s biotech space. This year, San Diego-based Amylin forged an alliance with India’s Biocon for a new peptide drug to treat diabetes. Amylin is expected provide phybrid technology in peptide hormone development for the candidate molecule, while Biocon will utilize its expertise in recombinant microbial expression to manufacture the compound and develop it through preclinical and early human studies.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !